Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis
Фармакогеномика тирзепатида: геномные аспекты ответа на двойной агонист GIP/GLP-1 при сахарном диабете 2 типа и атеросклерозе
2025-08-25
SCID: 54.1/v2m4jp5z
Discuss with AI
GIP/GLP-1 receptor agonistatherosclerosispersonalized therapytirzepatide pharmacogenomicstype 2 diabetes mellitus
Figures from the paper
Abstract (AI)
Type 2 diabetes mellitus (T2DM) is frequently complicated by atherosclerosis (AS), with substantial overlap in their underlying pathophysiological mechanisms, posing serious threats to patient health. Tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated remarkable efficacy in glycemic control, weight reduction, and cardiometabolic improvement, making it a promising candidate for managing T2DM comorbid with AS. However, substantial interindividual variability in treatment response suggests a role for genetic determinants. This review systematically summarises current evidence on pharmacogenomic variants influencing the efficacy and toxicity of tirzepatide, explores the interplay between drug response genes and genetic susceptibilities to T2DM and AS, and highlights the potential of pharmacogenomics in guiding precision subtyping and individualised therapy. Finally, we highlight key challenges and future directions in the clinical translation of tirzepatide pharmacogenomics, aiming to inform personalized, genomics-guided therapy for cardiometabolic disease.
Key Findings
1
Clinical translation of tirzepatide pharmacogenomics remains challenging and requires further research to establish genomics-guided treatment strategies.
2
Integrating drug-response genes with disease-risk genetics may support precision subtyping and individualized tirzepatide therapy.
3
Substantial interindividual variability in tirzepatide response indicates that genetic determinants may influence treatment efficacy and toxicity.
4
The review synthesizes evidence linking pharmacogenomic variants with tirzepatide response and with genetic susceptibility to T2DM and atherosclerosis.
5
Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows efficacy for glycemic control, weight reduction, and cardiometabolic improvement in T2DM with atherosclerosis.
Research Object
Tirzepatide treatment in patients with type 2 diabetes mellitus and atherosclerosis
Research Subject
Pharmacogenomic determinants of tirzepatide efficacy, toxicity, and interindividual treatment-response variability
Publication Details
Publication Date
2025-08-25
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest